Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

FibroGen Stock

FGEN
US31572Q8087
A12EZ0

Price

0.98
Today +/-
+0
Today %
+0 %
P

FibroGen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into FibroGen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by FibroGen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects FibroGen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of FibroGen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into FibroGen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing FibroGen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on FibroGen’s growth potential.

FibroGen Revenue, EBIT and net profit per share

DateFibroGen RevenueFibroGen EBITFibroGen Net Income
2029e286.62 M undefined0 undefined25.37 M undefined
2028e257.04 M undefined4.08 M undefined4.06 M undefined
2027e235.62 M undefined-28.56 M undefined-25.37 M undefined
2026e183.06 M undefined-87.75 M undefined-18.26 M undefined
2025e155.49 M undefined-51.29 M undefined-58.18 M undefined
2024e153.42 M undefined-128.2 M undefined-132.59 M undefined
2023147.75 M undefined-269.21 M undefined-284.23 M undefined
2022140.7 M undefined-301 M undefined-293.7 M undefined
2021235.3 M undefined-288.5 M undefined-290 M undefined
2020176.3 M undefined-191.9 M undefined-189.3 M undefined
2019256.6 M undefined-89.3 M undefined-77 M undefined
2018213 M undefined-86.7 M undefined-86.4 M undefined
2017131 M undefined-117.3 M undefined-120.9 M undefined
2016183.2 M undefined-50 M undefined-58.1 M undefined
2015180.8 M undefined-77.6 M undefined-85.8 M undefined
2014137.6 M undefined-50.1 M undefined-59.5 M undefined
2013102.2 M undefined-7.9 M undefined-14.9 M undefined
201265.9 M undefined-27.2 M undefined-32.6 M undefined

FibroGen Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
65102137180183131213256176235140147153155183235257286
-56.9234.3131.391.67-28.4262.6020.19-31.2533.52-40.435.004.081.3118.0628.429.3611.28
-------99.6194.8994.4785.7187.07------
0000000255167222120128000000
-27-7-50-77-50-117-86-89-191-288-301-269-128-51-87-2840
-41.54-6.86-36.50-42.78-27.32-89.31-40.38-34.77-108.52-122.55-215.00-182.99-83.66-32.90-47.54-11.911.56-
-32-14-59-85-58-120-86-77-189-290-293-284-132-58-18-25425
--56.25321.4344.07-31.76106.90-28.33-10.47145.4553.441.03-3.07-53.52-56.06-68.9738.89-116.00525.00
55.755.718.860.362.77384.186.689.992.393.697.3000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The FibroGen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the FibroGen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of FibroGen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand FibroGen's financial health and stability.

Assets

FibroGen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that FibroGen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of FibroGen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into FibroGen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-32-14-59-85-58-120-86-76-189-290-293-284
5545666212214109
000000000000
16315830249-48-851746070-119
9738586676104128146204132129
000000000000
000000000000
-52522-187-66-76-7881-82-145-315
0-6-8-1-1-8-8-5-3-30-38-2
1910-107-5669-522120452-42689153
1917-99-3778-514125456-396127156
000000000000
0000000-12-13-5070
00157129506292037125352
6017412649613-413046122
70160-2-9-15-12-11-7-60
000000000000
203789-1220499-58437552-507-15-42
-6.3519.1114.29-20.555.86-75.01-84.16-84.4777.61-112.42-184.67-317.54
000000000000

FibroGen stock margins

The FibroGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of FibroGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for FibroGen.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the FibroGen's sales revenue. A higher gross margin percentage indicates that the FibroGen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the FibroGen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the FibroGen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the FibroGen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the FibroGen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the FibroGen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

FibroGen Margin History

FibroGen Gross marginFibroGen Profit marginFibroGen EBIT marginFibroGen Profit margin
2029e87.24 %0 %8.85 %
2028e87.24 %1.59 %1.58 %
2027e87.24 %-12.12 %-10.77 %
2026e87.24 %-47.94 %-9.98 %
2025e87.24 %-32.98 %-37.41 %
2024e87.24 %-83.56 %-86.42 %
202387.24 %-182.2 %-192.37 %
202285.64 %-213.93 %-208.74 %
202194.52 %-122.61 %-123.25 %
202095.01 %-108.85 %-107.37 %
201999.53 %-34.8 %-30.01 %
201887.24 %-40.7 %-40.56 %
201787.24 %-89.54 %-92.29 %
201687.24 %-27.29 %-31.71 %
201587.24 %-42.92 %-47.46 %
201487.24 %-36.41 %-43.24 %
201387.24 %-7.73 %-14.58 %
201287.24 %-41.27 %-49.47 %

FibroGen Stock Sales Revenue, EBIT, Earnings per Share

The FibroGen earnings per share therefore indicates how much revenue FibroGen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue FibroGen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates FibroGen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of FibroGen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating FibroGen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

FibroGen Revenue, EBIT and net profit per share

DateFibroGen Sales per ShareFibroGen EBIT per shareFibroGen Earnings per Share
2029e2.88 undefined0 undefined0.26 undefined
2028e2.58 undefined0 undefined0.04 undefined
2027e2.37 undefined0 undefined-0.26 undefined
2026e1.84 undefined0 undefined-0.18 undefined
2025e1.56 undefined0 undefined-0.58 undefined
2024e1.54 undefined0 undefined-1.33 undefined
20231.52 undefined-2.77 undefined-2.92 undefined
20221.5 undefined-3.22 undefined-3.14 undefined
20212.55 undefined-3.13 undefined-3.14 undefined
20201.96 undefined-2.13 undefined-2.11 undefined
20192.96 undefined-1.03 undefined-0.89 undefined
20182.53 undefined-1.03 undefined-1.03 undefined
20171.79 undefined-1.61 undefined-1.66 undefined
20162.92 undefined-0.8 undefined-0.93 undefined
20153 undefined-1.29 undefined-1.42 undefined
20147.32 undefined-2.66 undefined-3.16 undefined
20131.83 undefined-0.14 undefined-0.27 undefined
20121.18 undefined-0.49 undefined-0.59 undefined

FibroGen business model

FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen is one of the most popular companies on Eulerpool.com.

FibroGen SWOT Analysis

Strengths

FibroGen Inc. possesses several strengths that contribute to its competitive advantage:

  • Strong portfolio of innovative and proprietary therapeutics
  • Advanced clinical pipeline with potential treatments targeting significant diseases
  • Established partnerships with reputable pharmaceutical companies
  • Experienced and talented research and development team
  • Strong financial position and access to funding for continued growth

Weaknesses

Despite its strengths, there are certain weaknesses that FibroGen Inc. needs to address:

  • Reliance on a limited number of product candidates
  • Regulatory challenges and potential delays in drug approval processes
  • High research and development costs
  • Vulnerability to intellectual property infringement
  • Dependence on partnerships for successful commercialization

Opportunities

FibroGen Inc. can leverage the following opportunities to drive future growth:

  • Increasing demand for effective treatments for chronic diseases
  • Expanding global pharmaceutical market
  • Advancements in biotechnology and pharmaceutical research
  • Potential collaborations and licensing agreements with other companies
  • Growing acceptance of novel therapeutic approaches

Threats

FibroGen Inc. faces several threats that may impede its success:

  • Intense competition from established pharmaceutical companies
  • Potential legal and regulatory challenges
  • Risks associated with clinical trials and drug development
  • Fluctuating market conditions and economic uncertainties
  • Loss of key personnel or failure to attract and retain top talent

FibroGen valuation based on historical P/E ratio, EBIT, and P/S ratio.

FibroGen shares outstanding

The number of shares was FibroGen in 2023 — This indicates how many shares 97.303 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue FibroGen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates FibroGen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of FibroGen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating FibroGen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for FibroGen.

FibroGen Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.43 -0.33  (22.97 %)2024 Q1
12/31/2023-0.43 -0.57  (-31.49 %)2023 Q4
9/30/2023-0.69 -0.52  (25.03 %)2023 Q3
6/30/2023-0.72 -0.9  (-25.45 %)2023 Q2
3/31/2023-0.77 -0.81  (-5.41 %)2023 Q1
12/31/2022-0.96 -0.7  (26.86 %)2022 Q4
9/30/2022-0.83 -0.98  (-18.62 %)2022 Q3
6/30/2022-0.96 -0.78  (18.36 %)2022 Q2
3/31/2022-0.85 -0.68  (19.84 %)2022 Q1
12/31/2021-0.68 -1.45  (-114.47 %)2021 Q4
1
2
3
4

Eulerpool ESG Scorecard© for the FibroGen stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

35

👫 Social

99

🏛️ Governance

52

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

FibroGen Stock Shareholders

%
Name
Stocks
Change
Date
9.82 % Armistice Capital LLC9,764,0001,872,00012/31/2023
7.08 % The Vanguard Group, Inc.7,044,149-2,016,79412/31/2023
6.72 % BlackRock Institutional Trust Company, N.A.6,680,111-705,09012/31/2023
4.99 % Astellas Pharma Inc4,968,36701/31/2023
3.94 % Two Sigma Investments, LP3,917,527406,29412/31/2023
2.54 % Jacobs Levy Equity Management, Inc.2,527,401-69,81212/31/2023
2.48 % Acadian Asset Management LLC2,468,928853,83412/31/2023
2.40 % Citadel Advisors LLC2,390,6811,140,23712/31/2023
2.24 % Assenagon Asset Management S.A.2,226,857012/31/2023
2.03 % Geode Capital Management, L.L.C.2,018,281133,32912/31/2023
1
2
3
4
5
...
10

FibroGen Executives and Management Board

Ms. Christine Chung55
FibroGen Senior Vice President, China Operations
Compensation 3.59 M
Mr. Thane Wettig58
FibroGen Chief Executive Officer, Director, Chief Commercial Officer (since 2020)
Compensation 3.12 M
Mr. Juan Graham47
FibroGen Chief Financial Officer
Compensation 2.15 M
Mr. James Schoeneck65
FibroGen Independent Chairman of the Board (since 2010)
Compensation 437,839
Ms. Suzanne Blaug65
FibroGen Independent Director
Compensation 356,954
1
2
3

FibroGen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alexandria Real Estate Stock
Alexandria Real Estate
SupplierCustomer0,850,370,760,61-0,11-0,78
WuXi AppTec Co H Stock
WuXi AppTec Co H
SupplierCustomer0,280,080,420,420,27-0,42
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,19-0,28-0,70-0,78-0,06-0,43
Catalent Stock
Catalent
SupplierCustomer-0,26-0,230,590,51-0,12-0,52
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,390,05-0,63-0,85-0,36-0,53
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer-0,54-0,030,480,50-0,41-0,77
Astellas Pharma Stock
Astellas Pharma
SupplierCustomer-0,680,28-0,53-0,45-0,03-0,71
1

FibroGen stock: Frequently Asked Questions

What values and corporate philosophy does FibroGen represent?

FibroGen Inc represents a commitment to innovative biopharmaceutical research and development. The company focuses on discovering, developing, and commercializing transformative therapies for unmet medical needs. FibroGen believes in a patient-centric approach, striving to improve the lives of individuals through groundbreaking medical advancements. With a strong emphasis on scientific excellence and a dedicated team, FibroGen pursues cutting-edge treatments and therapies to address diseases such as anemia, fibrosis, and cancer. The company's corporate philosophy is built on integrity, collaboration, and a drive for meaningful impact in the field of biotechnology. FibroGen Inc aims to bring hope and improved health outcomes to patients worldwide.

In which countries and regions is FibroGen primarily present?

FibroGen Inc is primarily present in the United States and China. With headquarters in San Francisco, California, the company operates in various states across the US, including California, Massachusetts, and Washington. In addition, FibroGen Inc has a significant presence in China, where it has established partnerships and collaborations for research, development, and commercialization of its products. This dual presence in the two prominent economies allows FibroGen Inc to target and cater to a larger market, maximizing its growth opportunities and expanding its global footprint.

What significant milestones has the company FibroGen achieved?

FibroGen Inc, a renowned biopharmaceutical company, has achieved several significant milestones. Firstly, the company received FDA approval for roxadustat, their breakthrough anemia treatment. Additionally, FibroGen Inc successfully completed Phase 3 clinical trials for roxadustat, establishing its efficacy and safety. The company also entered into strategic collaborations with global pharmaceutical giants, such as AstraZeneca and Astellas Pharma, to expand the reach of their innovative therapies. FibroGen Inc's dedication to research and development has led to the discovery of novel treatments for serious medical conditions, positively impacting patients worldwide. Their relentless pursuit of scientific advancements has earned them a prominent position in the biopharmaceutical industry.

What is the history and background of the company FibroGen?

FibroGen Inc. is a biopharmaceutical company known for its cutting-edge research and development in treating serious unmet medical needs. Established in 1993 and headquartered in San Francisco, California, FibroGen has been at the forefront of developing novel therapies to address conditions such as anemia, fibrosis, and cancer. The company's expertise lies in utilizing its advanced platform technologies, including tissue repair and fibrosis, to develop innovative treatments. FibroGen has successfully brought several drugs to market, including roxadustat, which treats anemia in patients with chronic kidney disease. Combining a deep commitment to scientific advancement and patient well-being, FibroGen strives to revolutionize healthcare with its groundbreaking pharmaceutical solutions.

Who are the main competitors of FibroGen in the market?

The main competitors of FibroGen Inc in the market include companies like Gilead Sciences, Inc., Akebia Therapeutics, Inc., and GlaxoSmithKline plc.

In which industries is FibroGen primarily active?

FibroGen Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of FibroGen?

FibroGen Inc has a business model focused on the development and commercialization of innovative therapies for serious unmet medical needs. The company specializes in the research and development of biologics, particularly in the areas of anemia, fibrosis, and cancer. FibroGen Inc collaborates with partners to advance their pipeline of potential medicines, aiming to improve the lives of patients worldwide. Through its scientific expertise and strategic collaborations, FibroGen Inc aims to bring new treatment options to market that address various disease indications and improve patient outcomes.

What is the P/E ratio of FibroGen 2024?

The FibroGen P/E ratio is -0.72.

What is the P/S ratio of FibroGen 2024?

The FibroGen P/S ratio is 0.62.

What is the AlleAktien quality score of FibroGen?

The AlleAktien quality score for FibroGen is 5/10.

What is the revenue of FibroGen 2024?

The expected FibroGen revenue is 153.42 M USD.

How high is the profit of FibroGen 2024?

The expected FibroGen profit is -132.59 M USD.

What is the business model of FibroGen

FibroGen Inc. is a biopharmaceutical company specializing in the development of innovative therapies for diseases such as anemia, cancer, and fibrosis. The company is headquartered in San Francisco and has branches in China and Denmark. The company's business model is based on researching and developing therapeutic molecules that stimulate the body's production of natural hormones and erythropoietin (EPO). FibroGen has developed a proprietary technology platform for developing novel drugs based on specific biological mechanisms. Their research and development focus includes anemia treatment, cancer treatment, and fibrosis treatment. They have developed products such as Roxadustat for anemia in chronic kidney disease, Pamrevlumab for cancer treatment, and Pamrevlumab for idiopathic pulmonary fibrosis and systemic sclerosis. They also have partnerships with other pharmaceutical companies like Astellas and AstraZeneca to bring their products to market.

What is the FibroGen dividend?

FibroGen pays a dividend of 0 USD distributed over payouts per year.

How often does FibroGen pay dividends?

The dividend cannot currently be calculated for FibroGen or the company does not pay out a dividend.

What is the FibroGen ISIN?

The ISIN of FibroGen is US31572Q8087.

What is the FibroGen WKN?

The WKN of FibroGen is A12EZ0.

What is the FibroGen ticker?

The ticker of FibroGen is FGEN.

How much dividend does FibroGen pay?

Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.

What is the dividend yield of FibroGen?

The current dividend yield of FibroGen is .

When does FibroGen pay dividends?

FibroGen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of FibroGen?

FibroGen paid dividends every year for the past 0 years.

What is the dividend of FibroGen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is FibroGen located?

FibroGen is assigned to the 'Health' sector.

Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of FibroGen from 7/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did FibroGen pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of FibroGen in the year 2023?

In the year 2023, FibroGen distributed 0 USD as dividends.

In which currency does FibroGen pay out the dividend?

The dividends of FibroGen are distributed in USD.

Other fundamentals and analyses of FibroGen in the deep dive.

Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.